Patents by Inventor Vittal SHIVVA

Vittal SHIVVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TIE2-BINDING AGENTS AND METHODS OF USE
    Publication number: 20260103527
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: December 12, 2025
    Publication date: April 16, 2026
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie DiCara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • TIE2-BINDING AGENTS AND METHODS OF USE
    Publication number: 20240327528
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: March 19, 2024
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie DiCara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS FOR THE EXPANSION OF NK CELLS IN THE TREATMENT OF SOLID TUMOURS
    Publication number: 20240216473
    Abstract: The present disclosure provides methods of treating cancer by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion and either increasing the number of NK cells at least 20-fold as compared to the number of NK cells prior to said administration or resulting in the accumulation of NK cells in the subject. The present disclosure also provides methods for inducing the proliferation of NK cells by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion and either increasing the number of NK cells at least 20-fold as compared to the number of NK cells prior to said administration or resulting in the accumulation of NK cells in the subject.
    Type: Application
    Filed: February 2, 2024
    Publication date: July 4, 2024
    Inventors: Shomyseh Sanjabi, Vittal Shivva, Alexander Joachim Paul Ungewickell, Rajbharan Yadav
  • Tie2-binding agents and methods of use
    Patent number: 11999787
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: June 4, 2024
    Assignee: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie Dicara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS FOR THE TREATMENT OF CANCER
    Publication number: 20230149509
    Abstract: The present disclosure provides methods of treating cancer by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15R? protein-Fc domain fusion.
    Type: Application
    Filed: July 22, 2022
    Publication date: May 18, 2023
    Inventors: Alexander Joachim Paul Ungewickell, Vittal Shivva, Rajbharan Yadav
  • TIE2-BINDING AGENTS AND METHODS OF USE
    Publication number: 20210332142
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: March 22, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Minhong YAN, Gu ZHANG, Nicholas John AGARD, Danielle Marie DICARA, Philip E. HASS, Julie Q. HANG, Erin L. CHRISTENSEN, Robert Paul MORSE, Sarah SANOWAR, Vittal SHIVVA